Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL;...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

lensplay Mar. 18 at 9:52 PM

$AUTL based on history I wouldn't count on anything positive from the ER. All the CEO does on these calls is overstate the negatives which so far have been proven to have no or little actual impact on the business yet were terrible for the SP. he warned about tarrifs. no impact but stock took a hit. he warned of the split billing. no or little impact, stock took a hit. he said holidays might be bad, no or little impact but stock took a big hit. when he talks the stock goes down. its just facts. the only time the stock had any real life was the few months before biontech partnership which obviously someone already knew about and ran up the stock. he has been a total disaster for the SP. that is just fact.

1 · Reply

diggs24 Mar. 18 at 7:55 PM

$AUTL Come to papa Diggs.....

1 · Reply

smar312 Mar. 18 at 2:20 PM

$AUTL Gift 🎁

0 · Reply

bangguman Mar. 18 at 1:47 PM

$AUTL I'll stay on the sidelines until a clear direction is established.

1 · Reply

nopennys Mar. 18 at 11:42 AM

$AUTL can we expect some surprises during the upcoming earnings call? EU revenue earlier than expected? Partnerships? Something to lift the stock lol

1 · Reply

Michael_garic Mar. 17 at 1:17 PM

$AUTL March calls expire on Friday. Expect market makers to try and manipulate the price to $1.50 or lower unless some unexpected news breaks. April shows 100 calls to 1 put. Most folks still betting on AUTL to break out.

1 · Reply

nopennys Mar. 16 at 9:56 PM

$AUTL Earnings on 27th March https://autolus.gcs-web.com/events/event-details/financial-results-fourth-quarter-2025-conference-call

0 · Reply

TricksterT Mar. 16 at 8:42 PM

Autolus Therapeutics Q4 and 2025 results call Mar. 27 | AUTL Stock News $AUTL Wow that’s late! https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2025-v3ro5ghezk0r.html

0 · Reply

AshvsEvilDead Mar. 16 at 3:11 PM

$AUTL I bought more here. If their CAR-T captures even a small slice of the CD19 leukemia market, the revenue potential looks far larger than this current stock price implies. Undervalued relative to revenue growth.

0 · Reply

nopennys Mar. 16 at 2:43 PM

$AUTL will this be the last opportunity to buy shares this cheap?

0 · Reply

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Feb 24, 2026, 7:00 AM EST - 22 days ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Feb 4, 2026, 8:57 AM EST - 6 weeks ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 7:00 AM EST - 2 months ago

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Jan 6, 2026, 9:00 AM EST - 2 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

Jan 6, 2026, 9:00 AM EST - 2 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

$Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025$

Dec 8, 2025, 4:05 PM EST - 3 months ago

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 8, 2025, 8:35 AM EST - 3 months ago

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 1, 2025, 7:00 AM EST - 3 months ago

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

Nov 25, 2025, 12:37 PM EST - 4 months ago

Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?

$NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹$

Nov 25, 2025, 4:00 AM EST - 4 months ago

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Nov 14, 2025, 10:28 AM EST - 4 months ago

Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline

Nov 13, 2025, 4:05 PM EST - 4 months ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 3:11 PM EST - 4 months ago

Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:00 AM EST - 4 months ago

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 3, 2025, 9:05 AM EST - 4 months ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Oct 20, 2025, 7:00 AM EDT - 5 months ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Sep 16, 2025, 8:05 AM EDT - 6 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Aug 12, 2025, 5:26 PM EDT - 7 months ago

Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable

Aug 12, 2025, 4:37 PM EDT - 7 months ago

Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jul 24, 2025, 7:30 AM EDT - 8 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

$Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

Jul 21, 2025, 7:00 AM EDT - 8 months ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jun 12, 2025, 2:00 AM EDT - 9 months ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 6, 2025, 11:09 AM EDT - 10 months ago

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 10 months ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 20, 2025, 5:47 AM EDT - 10 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC CAPR CLPT EDIT NTLA VANI VERV

May 14, 2025, 9:30 AM EDT - 11 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 11, 2025, 4:22 AM EDT - 11 months ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 11 months ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 11 months ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 11 months ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 22, 2025, 7:00 AM EDT - 11 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 11:55 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 6, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 4, 2025, 10:21 AM EST - 1 year ago

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Jan 17, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 12:16 AM EST - 1 year ago

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 12, 2024, 2:57 PM EST - 1 year ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 1 year ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Sep 6, 2024, 2:12 PM EDT - 1 year ago

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Aug 10, 2024, 12:05 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

lensplay Mar. 18 at 9:52 PM

1 · Reply

diggs24 Mar. 18 at 7:55 PM

$AUTL Come to papa Diggs.....

1 · Reply

smar312 Mar. 18 at 2:20 PM

$AUTL Gift 🎁

0 · Reply

bangguman Mar. 18 at 1:47 PM

$AUTL I'll stay on the sidelines until a clear direction is established.

1 · Reply

nopennys Mar. 18 at 11:42 AM

$AUTL can we expect some surprises during the upcoming earnings call? EU revenue earlier than expected? Partnerships? Something to lift the stock lol

1 · Reply

Michael_garic Mar. 17 at 1:17 PM

1 · Reply

nopennys Mar. 16 at 9:56 PM

$AUTL Earnings on 27th March https://autolus.gcs-web.com/events/event-details/financial-results-fourth-quarter-2025-conference-call

0 · Reply

TricksterT Mar. 16 at 8:42 PM

0 · Reply

AshvsEvilDead Mar. 16 at 3:11 PM

0 · Reply

nopennys Mar. 16 at 2:43 PM

$AUTL will this be the last opportunity to buy shares this cheap?

0 · Reply

resume777 Mar. 16 at 12:31 PM

$AUTL Can expect the Annual Filing to drop by end of week and likely reiterate what was said at TD Cowen early March 2026. "Autolus reported $75 million in revenue from the first year of Catsl’s launch, achieving market leadership in the second quarter. The company aims for $120 million-$135 million in net revenue for the current year, with a move to positive gross margins. Expansion plans include increasing U.S. treatment centers to over 80 and advancing studies in pediatric ALL, lupus nephritis, and progressive MS. The ROCCA database supports Catsl’s safety profile with low rates of high-grade CRS and ICANS. Autolus is enhancing manufacturing efficiency through cost optimization and automation." 2025: March 20, 2025 2024: March 21, 2024 2023: March 7, 2023 2022: March 6, 2022 https://www.investing.com/news/transcripts/autolus-at-td-cowen-conference-strategic-expansion-and-optimism-93CH-4538796"

0 · Reply

Michael_garic Mar. 15 at 12:06 PM

$AUTL This is data from ROCCA, a Stanford University led independent research organization, that tracks actual patient outcomes. The data shows that AUTL is the leader in efficacy and safety by a good margin. The safety aspect is important because it allows AUTL to treat patients in an outpatient setting. Outpatient treatment is a positive for AUTL as they don't have to compete for scarce ICU bed/space to treat their patients and opens up capacity for more patients. Below is the competitive chart based on REAL patient outcomes. Note that Kymriah is a pediatric treatment. It won't be that much longer that the AUTL coiled spring will pop and the stock price will not linger at cash value, ignoring the value of Aucatzyl for both oncology and immunotherapy. AUTL is a real, viable, commercial biotech. 2026 will prove that point.

1 · Reply

Joe_90_ Mar. 15 at 9:11 AM

$AUTL looking for some info, as you know BNTX dropped 17% last week, and subsequently improved as founders Ugur Sahin (CEO) and Ozlem Tureci (CMO) announced they are leaving to establish a new biotech firm. So where does this leave $AUTL, while the CEO will remain in place for the moment, if anyone has a POC we really need some statement on this.

1 · Reply

keypatience Mar. 14 at 4:59 PM

$AUTL Everyone knows how AI Slop reads like. Your writing is unnatural. Nobody writes like that and it’s very clear you are writing with AI.

4 · Reply

Michael_garic Mar. 14 at 4:46 PM

$AUTL Not AI my friend, I spend a lot of time trying to find information that may be helpful to others. One man's slop is another man's treasure. Take care and have a wonderful day.

3 · Reply

Michael_garic Mar. 14 at 4:43 PM

$AUTL

0 · Reply

keypatience Mar. 14 at 12:15 PM

$AUTL AI slop….

1 · Reply

Michael_garic Mar. 14 at 12:12 PM

$AUTL AUTL financials show 259M in debt. This is not debt as we think of it but is the estimated royalties from investments. Money is only paid back based on revenue. AUTL has to pay royalties(estimated) for investment money and to the founders based on revenue: Estimated Entity Investment AUTL pays Blackstone 250M 5% - 6% BioNTech 200M 2% - 4% UCL Business owns patent 2% - 3% AUTL keeps about 90% of the revenue it generates. Conversely AUTL has money coming in from licenses: RQR8 kill switch licensed to: Bristol Meyers Moderna Cabaletta bio CABA Additionally BioNTech is renting space at the AUTL manufacturing facility and is licensing AUTL's binders in their CAR T drug trials. These licenses could lead to a lot of revenue if the trials move into production.

1 · Reply

Michael_garic Mar. 14 at 11:39 AM

$AUTL Currently AUTL is priced like a biotech that is distressed vs. a commercially viable, revenue generating business. With revenue of 135M AUTL is at a multiple less than 3. Industry Average is 6.0, Bullish is 8.0. If the earnings announcement gives specifics on when/how AUTL will achieve positive gross margin they could hit the 6.0 or 8.0 multiple number. Assume the 135M revenue number for 2026 Current multiple 2.9 - 1.44 6.0/8.0 Multiple 3.00 to 4.00 range

1 · Reply

Michael_garic Mar. 14 at 8:52 AM

$AUTL Things I've learned from CAR T research. China is the leader in CAR T trials and pricing, but several companies have been caught "copying and pasting" trial data. Because of this the Biosecure Act was created. The government created a "watchlist" of Chinese companies not in compliance. A Western company that uses any services from these companies must disclose the relationship and MAY have to rerun trials and/or break the relationship. FDA has also created a system to audit Chinese data by the FDA or "Western Vetted" auditor. All previous data is considered invalid. AUTL does not use Chinese data or manufacturing and is not conducting trials in China. AUTL competitors CABA (Cabaletta) and KYTX (Kyverna) MAY be affected. CABA is in the process of costly reshoring and is at the most risk as they were using Wuxi Apptech for viral vector mfg, analytical and safety testing and Early-Stage chemistry/mfg testing. KYTX used German and Chinese data. Impact unknown.

0 · Reply

Michael_garic Mar. 14 at 7:53 AM

$AUTL We should all know that AUTL is not concerned about the stock price short-term. I believe that they have learned from other biotech failures trying to generate revenue at all costs without reducing burn rate, over projecting and under delivering. Yes, they had a stock bump in the short term but crashed later. AUTL is trying to build a sustainable long-term business. Steady growth and managing costs. AUTL has a large institutional base with 70% ownership. They don't day trade and worry about short-term stock price. This is due diligence for the institutional owners. They can't worry about the retail investor's feelings. While many retail stockholders feel the company should do whatever it takes to protect or increase the stock price, that is not what a prudent start up does. How many biotechs have crashed trying to create "get rich quick" schemes for the investors and themselves making some folks rich, but many poor?

0 · Reply

nopennys Mar. 13 at 4:21 PM

$AUTL when is the next earnings call? I wasn't able to find it on their website Thanks

1 · Reply

Market Cap	383.25M
Revenue (ttm)	10.12M
Net Income (ttm)	-220.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,180.43%
Debt to Equity Ratio	0.00

Volume	951,800
Avg Vol	1,864,210
Day's Range	N/A - N/A
Shares Out	266.14M
Stochastic %K	33%
Beta	1.95
Analysts	Strong Sell
Price Target	$8.99